The safety of duloxetine during pregnancy and lactation

Journal of Clinical Psychiatry

Volumn 75, Issue 12, 2014, Pages e1423-e1427

  Andrade, Chittaranjan ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; ANTIDEPRESSANT AGENT; THIOPHENE DERIVATIVE;

ARTICLE; BREAST MILK; DEPRESSION; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG SAFETY; ECTOPIC PREGNANCY; FETUS MALFORMATION; HUMAN; LACTATION; MATERNAL PLASMA; NEONATAL ADAPTATION SYNDROME; NEWBORN DISEASE; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SPONTANEOUS ABORTION; STILLBIRTH; THIRD TRIMESTER PREGNANCY; CHEMICALLY INDUCED; DRUG ADMINISTRATION; DRUG EFFECTS; EPIDEMIOLOGY; FEMALE; INFANT; METABOLISM; PHYSIOLOGY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; LACTATION; MILK, HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; THIOPHENES;

EID: 84932138540     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/jcp.14f09631     Document Type: Article

References (39)

1. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004;103(4):698-709.
2. Gavin NI, Gaynes BN, Lohr KN, et al. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005;106(5 pt 1):1071-1083.
3. Davalos DB, Yadon CA, Tregellas HC. Untreated prenatal maternal depression and the potential risks to offspring: a review. Arch Women Ment Health. 2012;15(1):1-14.
4. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499-507.
5. Grote NK, Bridge JA, Gavin AR, et al. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010;67(10):1012-1024.
6. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand. 2013;127(2):94-114.
7. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74(4):e321-e341.
8. Parry BL. Assessing risk and benefit: to treat or not to treat major depression during pregnancy with antidepressant medication. Am J Psychiatry. 2009;166(5):512-514.
9. Koren G, Nordeng H. Antidepressant use during pregnancy: the benefit-risk ratio. Am J Obstet Gynecol. 2012;207(3):157-163.
10. Sie SD, Wennink JM, van Driel JJ, et al. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed. 2012;97(6):F472-F476.
11. Cooper WO, Willy ME, Pont SJ, et al. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol. 2007;196(6):e1-e5.
12. Huybrechts KF, Palmsten K, Mogun H, et al. National trends in antidepressant medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry. 2013;35(3):265-271.
13. Jimenez-Solem E. Exposure to antidepressants during pregnancy - prevalences and outcomes. Dan Med J. 2014;61(9):B4916.
14. Boyce PM, Hackett LP, Ilett KF. Duloxetine transfer across the placenta during pregnancy and into milk during lactation. Arch Women Ment Health. 2011;14(2):169-172.
15. Khan AY, Macaluso M. Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat. 2009;5:23-31.
16. Einarson A, Smart K, Vial T, et al. Rates of major malformations in infants following exposure to duloxetine during pregnancy: a preliminary report. J Clin Psychiatry. 2012;73(11):1471.
17. Hoog SL, Cheng Y, Elpers J, et al. Duloxetine and pregnancy outcomes: safety surveillance findings. Int J Med Sci. 2013;10(4):413-419.
18. Kjaersgaard MI, Parner ET, Vestergaard M, et al. Prenatal antidepressant exposure and risk of spontaneous abortion: a population-based study. PLoS ONE. 2013;8(8):e72095.
19. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74(4):e309-e320.
20. Eyal R, Yaeger D. Poor neonatal adaptation after in utero exposure to duloxetine. Am J Psychiatry. 2008;165(5):651.
21. Abdy NA, Gerhart K. Duloxetine withdrawal syndrome in a newborn. Clin Pediatr (Phila). 2013;52(10):976-977.
22. Bellantuono C, Marini A, Lucarelli C. Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine. Clin Drug Investig. 2013;33(9):685-688.
23. Briggs GG, Ambrose PJ, Ilett KF, et al. Use of duloxetine in pregnancy and lactation. Ann Pharmacother. 2009;43(11):1898-1902.
24. Lobo ED, Loghin C, Knadler MP, et al. Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. Clin Pharmacokinet. 2008;47(2):103-109.
25. Sachs HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013;132(3):e796-e809.
26. Andrade C. Antenatal exposure to selective serotonin reuptake inhibitors and duration of gestation. J Clin Psychiatry. 2013;74(7):e633-e635.
27. Huybrechts KF, Sanghani RS, Avorn J, et al. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS ONE. 2014;9(3):e92778.
28. Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand. 2010;121(6):471-479.
29. Udechuku A, Nguyen T, Hill R, et al. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry. 2010;44(11):978-996.
30. Deligiannidis KM, Byatt N, Freeman MP. Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol. 2014;34(2):244-255.
31. Knadler MP, Lobo E, Chappell J, et al. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011;50(5):281-294.
32. Waldschmitt C, Vogel F, Pfuhlmann B, et al. Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey. Pharmacopsychiatry. 2009;42(5):189-193.
33. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009;114(3):703-713.
34. Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-541.
35. Kumar N, Sangeetha D, Reddy PS, et al. Development and validation of a dissolution test for delayed release capsule formulation of duloxetine hydrochloride. Curr Pharmaceutical Anal. 2012;8(3):236-246.
36. Fritel X, Ringa V, Quiboeuf E, et al. Female urinary incontinence, from pregnancy to menopause: a review of epidemiological and pathophysiological findings. Acta Obstet Gynecol Scand. 2012;91(8):901-910.
37. Sangsawang B. Risk factors for the development of stress urinary incontinence during pregnancy in primigravidae: a review of the literature. Eur J Obstet Gynecol Reprod Biol. 2014;178:27-34.
38. Li J, Yang L, Pu C, et al. The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis. Int Urol Nephrol. 2013;45(3):679-686.
39. Smith AL, Wein AJ. Urinary incontinence: pharmacotherapy options. Ann Med. 2011;43(6):461-476.